1.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0358, NCT00398983
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DACO-016, NCT00260832
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-06054, NCT00382200
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0704-07 IUCRO-0185, NCT00477386
|
|
5.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCI 07-008, NCT00715793
|
|
6.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: 08-0172, NCT00691938
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0450, NCT00791271
|
|
8.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR015406, NCT00796003
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-13327A, NCI-6814, 6814, NCT00095784
|
|
10.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 15 to 59 Sponsor: NCI Protocol IDs: CALGB-10503, NCT00416598
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2006-0686, NCT00414310
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: OSU-07017, OSU-IRB-2007C0020, 07017, 7902, NCT00492401
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DACO-026, NCT00619099
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 00011792, 7667A, NCT00621023
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC0788, MC0788, NCT00630994
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: BrUOG-AML-217, MGI Pharma#DAC 022/2007, NCT00740181
|
|
17.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CRUK-PH2/051, PH2/051, EUDRACT-2006-002324-41, MGI-CRUK-PH2/051, CTA-21106/0219/001, DACROC, NCT00748527
|
|
18.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR014785, NCT00744757
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: 2007-0039, NCT00778375
|
|
20.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 60 Sponsor: NCI Protocol IDs: UMN-2008LS112, 2008LS112, 0810M50401, MT2008-29R, NCT00882206
|
|
21.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: Over 60 Sponsor: Other Protocol IDs: 00332, NCT00867672
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2008-0288, NCT00882102
|
|
23.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-02-C-0205, NCI-5270, 5270, NCT00041158
|
|
24.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-046, 6869, NCI-6869, NCT00275080
|
|
25.
|
Phase: Phase I Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 2005-0895, NCT00349596
|